A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations

A Phase Ib/IIa Study to Evaluate the Safety and Preliminary Efficacy of WX390, a PI3K/mTOR Dual Inhibitor, for the Treatment of Advanced Solid Tumors With PIK3CA Mutations

NCT06132932•Shanghai Jiatan Pharmatech Co., Ltd

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 in patients with advanced solid tumors. The main question it aims to answer is: • safety and preliminary efficacy in WX390 therapy. Participants will be treated with WX390 orally and follow the efficacy and safety evaluation according to the protocol.

Detailed Description

This study is a multicenter, open-label phase Ib/IIa clinical trial for patients with advanced solid tumors who have failed standard treatment. The study adopts a basket design, divided into 6 cohorts, with a total of 70-80 advanced solid tumor patients with PIK3CA mutations enrolled. Participants will receive WX390 treatment administered continuously daily, with each cycle lasting 28 days, until disease progression or intolerable toxicity occurs. During the study, safety and efficacy will be evaluated, with efficacy assessment based on RECIST 1.1. In addition, the study will collect tumor tissue or blood samples from the participants to explore the relationship between other biomarkers and treatment efficacy, as well as the impact of changes in PIK3CA mutation status before and after treatment on efficacy.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•18-75 years of age
•Histologically or cytologically confirmed advanced malignant solid tumors (excluding non-small cell lung cancer) who have failed standard treatment, have no standard treatment options, or for whom standard treatment is not suitable at the current stage (colorectal cancer patients must provide genetic test results confirming KRAS wild-type)
•Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
•Life expectancy of more than 3 months
•At least one measurable lesion according to RECIST 1.1
•Adequate organic function
•Signed and dated informed consent

Exclusion Criteria

•Anti-tumor treatments such as chemotherapy, radiotherapy, biological therapy, endocrine therapy, or immunotherapy received within 4 weeks before the first use of the study drug
•Other unapproved clinical trial drugs or treatments received within 4 weeks before the first use of the study drug
•Major organ surgery (excluding biopsy) or significant trauma within 4 weeks before the first use of the study drug
•Systemic use of corticosteroids or other immunosuppressive agents within 14 days before the first use of the study drug
•Previous treatment with PI3K, AKT, or mTOR inhibitors
•Active infection requiring systemic anti-infection treatment
•Known alcohol or drug dependence
•Individuals with mental disorders or poor compliance
•Pregnant or lactating women
•The researcher believes that the subject has other serious systemic medical history or other reasons that make them unsuitable for participating in this clinical study

Locations (1)

Shanghai East Hospital

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

June 3, 2021

Primary Completion Date

January 3, 2023

Completion Date

January 3, 2023

Last Updated

November 15, 2023

Enrollment

ACTUAL participants

Conditions

PIK3CA Mutation-Related Tumors

Interventions

WX390

DRUG

Breast Cancer PET/CT Imaging With 68Ga-pAKTi

NCT06943313

Breast CancersPIK3CA Mutation-Related Tumors+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 15, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions